8-OH DPAT |
|
5-HT1AR/5-HT7R agonist |
decreased mGluR-mediated LTD, prevented internalization of AMPA receptors [43]; normalization of respiratory function [77] |
(+)-5-FPT |
|
5-HT1AR/5-HT2CR/5-HT7R agonist |
reduction of stereotypic behavior, social activity increase [65]; reduced the number of audiogenic seizures [78] |
aripiprazole |
|
partial 5-HT1AR/ HT2AR/5-HT2CR/5-HT7R/D1R/D2R/D3R/D4R/D5R agonist; 5-HT1BR/5-HT1DR/5-HT2AR/5-HT2CR/5-HT3AR/HT6R/5-HT7R/D1R/D2R/D3R/ D4R/D5R/some alpha adrenergic and histamine receptors antagonist |
irritability amelioration [14,15,66] |
risperidone |
|
5-HT1A/5-HT1DR/5-HT2AR/5-HT2CR/5-HT7R/D1R/D2R/some alpha adrenergenic and histamine receptors antagonist |
irritability and aggressive behavior amelioration [17,18,66] |
lurasidone |
|
5-HT1AR/5-HT2AR/5-HT7/D2R/ some alpha adrenergic receptors antagonist; 5-HT1AR partial agonist |
irritability and aggressive behavior amelioration [19,66] |
1
|
|
5-HT1AR/5-HT7R agonist |
metabolically stable and have suitable CNS druglike properties [67] |
2
|
|
5-HT1AR/5-HT7R agonist |
metabolically stable and have suitable CNS druglike properties [67] |
3
|
|
5-HT1AR/5-HT7R agonist; 5-HT2BR antagonist |
metabolically stable and have suitable CNS druglike properties [67] |
LP-211 |
|
5-HT7R agonist; affinity to 5-HT1AR/D2R |
neurite growth promotion (increased the number of dendritic spines and synaptic connections) [54,68,69]; decreased mGluR-mediated LTD, prevented internalization of AMPA receptors [43,44]; reduction of stereotypic behavior, improvement of recognition memory [38,39]; anxiety alleviation, exploratory behavior and learning ability improvement [38,39]; normalization of mitochondrial ETC function [40,41] |